

Sent via email: [Appeals@nice.org.uk](mailto:Appeals@nice.org.uk)

Tim Irish  
Vice Chair  
National Institute for Health and Care Excellence

31 July 2019

Dear Tim,

**Final Evaluation Document withdrawal - metreleptin for treating lipodystrophy [ID861]**

I write to advise you that we have reviewed the request by Aegerion to have metreleptin reconsidered in line with the reconsideration step outlined in the HST Interim Methods and Process guide as referenced in their appeal letter. We note its intention to provide a more developed evidence base and a new value proposition for consideration by the HST committee. Consequently, we have agreed to retract the Final Evaluation Document issued on 6 of June 2019 and postpone the evaluation until the company is ready to resubmit its case for review.


This approach will give the company and stakeholders the appropriate time and opportunity to develop their evidence base, during which time the company has agreed to continue compassionate use of the drug for those patients already having metreleptin.

I trust this approach is acceptable to the Appeal Panel.

We will liaise with the corporate office team on communication to appellants and our wider consultee and commentator groups.

Kind regards

  
Associate Director Highly Specialised Technologies

Cc , Programme Director Technology Appraisals and Highly Specialised Technologies